Search
The Society of Memorial Sloan Kettering Cancer Center (MSK), an organization of dedicated volunteers, raised an extraordinary $6.6 million in their 2022–2023 season, fueling innovations in cancer care, research, and education.
In this Q&A, medical oncologist Martee Hensley discusses the diagnosis and treatment of leiomyosarcoma and other uterine sarcomas.
Women who have reconstructive surgery after mastectomy and radiation for breast cancer are usually more satisfied with the results when their own tissue is used instead of implants.
A new drug for ovarian cancer, which was developed based on lab research at MSK, is transforming the possibilities for patients like Ellen Coopersmith.
The Thoracic Surgery Oncology Group (TSOG) is a joint initiative between the American Association for Thoracic Surgery and the Fiona & Stanley Druckenmiller Center for Lung Cancer Research at Memorial Sloan Kettering Cancer Center (MSK).
The Peritoneal Surface Malignancies Consortium Group is a national, multidisciplinary collaboration of surgical and medical gastrointestinal oncology specialists from top cancer centers. The group recently published a series of updated consensus guidelines for the clinical management of peritoneal metastases related to a variety of gastrointestinal malignancies. In this Q&A with Dr. Michael Foote we discuss discuss the major updates for the management of colorectal cancer and appendiceal cancer peritoneal metastases and how the changes will improve patient outcomes and streamline patient care.
Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.
The broad-spectrum antibiotic piperacillin-tazobactam used as perioperative prophylaxis significantly reduced surgical site infection (SSI) in patients undergoing open pancreatoduodenectomy (PD, or the Whipple procedure) compared with the standard-of-care cefoxitin, according to results from the first-ever registry-linked surgical clinical trial conducted in North America. The findings, published in JAMA on April 20, support using piperacillin-tazobactam as a standard of care for this patient population.
Dr. Brown, whose research has been shedding light on the development of the early life immune system and its relationship to autoimmunity, allergy, inflammation and cancer, was among 30 early career scientists nationwide selected for the 2025 class of scholars.
Learn about some of the most important advances in cancer treatment at MSK in 2025.